1413 Pinnacle View Dr. NE Albuquerque, NM 87112-6558


D-fence Solutions, Inc. is a Public Health and Safety company dedicated to solving the world’s most challenging threats to personal health and safety through a number of the latest advances in microelectronics technologies. DSI is applying the most recent breakthroughs in gallium-nitride MOSFET devices; metamaterials for acoustic, optical, radar and 5/6G communications applications; and the highest performance System-on-Interconnect-Fabric (SoIF) computers to control these high-performance devices in a way that maximizes SWaP-C in every application.

Frederick L. Newton
Chairman, D-fence Solutions, Inc.

The Design Features, Operational Objectives, Preclinical and Clinical Trials Of DSI’s Virus Vaccine & Destruction Device (V2D2)

At the center of most all of the patents DSI is using in these applications is an incredible energy beam operating in the low gigahertz bands from K-band to 100 GHz in the W-band.  All of the transmitters over these frequencies are very small, energy efficient and tunable over the entire band.  DSI is using these beams operating at ~95GHz in non-lethal Reactive Deterrence™ products for borders, schools, most all public places, homes and even for hand-held personal defense.  The “heat beam”, sometimes referred to as the “pain beam”, penetrates a human’s skin only 1/64 of an inch to reach the nerve-endings for sensing hot and cold so the target experiences high pain but only for minutes with no permanent damage to human cells.

It is this remarkable K-W-band beam that brings us to the subject of destroying a portion of the COVID-19 virus in patients in record time while simultaneously creating a vaccine within patients that effectively destroys the remaining COVID-19 virus faster than any other vaccine or therapeutic drug.  Furthermore, and of even greater importance, this proposed device will be tunable to destroy most all viruses.

Over the spectrum of existing and future virus vaccines and therapeutics, let us first describe the present and near-term future approaches to virus prevention and therapeutic cures in general as well as that for COVID-19 in particular.  While we will draw upon a number of sources, we refer you to an excellent summary in seven articles published in the June 2020 issue of Scientific American.  Despite our high regard for the magazine, one of those articles is entitled “The Vaccine Quest: Only Genetic Engineering Can Create a Protective Serum in Months Rather Than Years”.  While the claim has remained true up to now, DSI intends to prove this claim to be false.

We return to 1796 when a smallpox vaccine was invented followed by vaccines for measles, mumps and rubella.  That process began with obtaining vaccinia from cowpox blisters which were similar but weaker than smallpox.  A body’s response was to develop a resistance to both.  But the vaccinia first had to be removed and carefully injected in the subject to be vaccinated. In recent years, virus particles have been removed from patients and altered in several ways:

  1. Attenuated, or weakened
  2. Inactivated, destroyed or killed, or
  3. Broken into pieces, or subunits.

This process of removing virus particles from patients and weakening or destroying the particles is time-consuming before reinjecting them back into the patient.  If we could somehow quickly break the virus particles apart without damaging other healthy cells, the patient’s response would be to generate antibodies that would continue to destroy other particles from the same virus.

Before we move on to how DSI has found a fast, safe, reliable way to destroy viruses and create vaccines in the process, we should first consider the more complex alternative — genetic engineering.  Gene-based vaccines begin by studying the genome of the virus to produce antigens.  The genetic instructions are programed into RNA or DNA molecules that are injected into the human cells.  In the case of COVID-19, the drug labs are racing to find ways to force the cells of humans to produce spike proteins, like the spike on the outside of a COVID-19 particle that attaches itself to a human cell and then works to enter that cell.

There are basically three ways the labs are trying to make the spike protein that is the antigen against COVID-19:

  1. A DNA-plasmid molecule — however, plasmids have trouble penetrating human cell membranes
  2. An RNA molecule — less stable than DNA-plasmids, easily degraded by common enzymes, and quickly destroyed by heat
  3. An Adenoviral Vector, which is a cold virus with the DNA inserted — good at getting into human cells but the immune system often detects, attacks and destroys them.

Limitations plague each of these three genetic engineering approaches.

Design Features and Operational Objectives

DSI’s V2D2 is described pictorially in the diagram below.

Referring to this diagram, a patient who tests positive for the COVID-19 virus could be seen at a hospital, clinic, doctor’s office or, preferably, at their home.  The V2D2 device is small enough to be carried in a standard physician’s bag.  It consists of the following elements:

  • IV needles, surgical tubing and valves for blood sampling and passing blood to the Virus Destruction Chamber
  • Small Virus Destruction Chamber (2.5 cm x 5 cm x 0.4 mm thick) covered by metamaterials (MTM) antenna arrays, GaN MIMICs array of K-W-band amps, and MTM oscillators for each virus type
  • Heat Exchanger Blood Cooling Unit with temperature sensor and control
  • Disposable Pump (0-10 ml/sec) — only moving part in the V2D2 device
  • Electric Pulse Generator for connection to the return IV line to stimulate cells near the injection site to open pores of cells to the vaccine (virus fragments).

Research at Arizona State University, Washington University at St. Louis and a few other universities in the U.S., UK and elsewhere have proven that virus particles have resonant frequencies at which vibrations shake and ultimately fracture and breakup portions of the virus particle (i.e., the outer fatty lipid protective layer or the inner capsid core).  For example, ASU found that the satellite tobacco necrosis virus has a resonant frequency at 60 GHz.

All of a patient’s blood supply flows from the IV and through the V2D2’s Virus Destruction Chamber.  Prior tests have shown the beam at 60 GHz and most other frequencies from 20 to 100 GHz does not damage healthy blood cells.

The Virus Destruction Chamber heats the blood somewhat as it passes through.  Therefore, the next step is to measure the temperature and cool the blood as it passes through the Heat Exchanger.

The cooled blood is finally drawn through the Disposable Pump that can be set at any speed up to 10 milliliters/second.  The entire blood supply of an average-sized adult can be passed through the V2D2 in about 15 minutes.  Standard cleansing of the V2D2 must be performed after each use and the disposable pump, the only moving part in the V2D2 device, must be replaced (~$10).

The processed blood is returned to the patient via the IV into the basilic vein.  That injected needle is also connected to the output of an Electric Pulse Generator Module built into the V2D2 device.  The electrical pulses fed to the IV return needle have been proven to stimulate the pores of human cells near the injection site, which enables virus fragments (i.e., vaccine) to enter the patient’s cells more easily, which makes the vaccine more effective in producing antigens.

After approximately 15 minutes of passing the patient’s blood supply through the V2D2 device, some, but not all, of the virus particles will be broken and fragmented by the high-frequency resonance.  Many virus particles will be missed in just one pass because the resonant frequency depends on the physical orientation of the virus particle to the beam direction.  However, the process of destroying the virus will have begun and the virus fragments will continue to destroy more virus particles and the process will continue until all are destroyed.  Best of all, the vaccine (broken virus fragments) will remain in the patient’s blood supply and serve as an effective vaccine for some yet undetermined period of time.

Finally, we believe most all viruses have their own resonant frequency for destruction.  Some, like the flu, change from year to year.  But another 15-minute IV may be all that is needed to update for that new form of virus.  The V2D2 may be easily and inexpensively updated for other viruses and prepared for operation by selecting the virus(es) on the control panel.  It is possible for two or more viruses to be destroyed simultaneously in one 15 to 20-minute procedure.  MIT’s invisible Quantum-Dot containing the date each vaccine was received could be placed under the skin with a microneedle for a 5-year record.


Preclinical and Clinical Trials

Prior to any trials, DSI intends to contract with Professor Eric Dykeman at York University in the UK for him and his staff to compute the predicted resonate frequencies for a number of viruses including COVID-19.  He and his staff are experienced in finding these resonances and have a specialized computer to speed the processing time.

Once in the lab with virus samples, tests to find the exact resonances can be conducted by beginning with the computed frequencies.  We note that actual resonance frequencies will vary with physical orientation of the virus particles to the direction of the beam in the Virus Destruction Chamber.

Each virus will have a center resonance frequency and deltas on either side as a result of orientation misalignment with the beam.

Additional Preclinical Trials will include:

  1. Testing solutions containing the virus fragments in animals (e.g., mice, ferrets or rhesus macaques) for toxicity
  2. Testing solutions containing the virus fragments in animals to determine if the vaccine prompts the immune system’s cells to produce antibodies that will identify and attach to the virus.

Clinical Trials will include three phases if Preclinical Trials are successful:

  1. (10-100 human subjects): Is the vaccine administered by IV safe?  Are bad side effects avoided?  Is there discomfort from the electric pulses at the IV entry point?  Does the immune system produce antibodies (antigens)?
  2. (100s of human subjects): Is the vaccine administered by IV safe?  Is the immune response strong?  Is the dosage correct?  Is there any discomfort?
  3. (10,000+ human subjects): Does it safely prevent infection and disease over a large number of people in a pain-free manner?

Once production of the V2D2 device has commenced, quality control and assurance must be maintained to ensure adherence to regulations and device specifications.

Leave a comment

You must be logged in to post a comment.